Researchers developed CheekAge, an epigenetic clock based on buccal cells, and found it predicted mortality risk with significant accuracy. This study validates CheekAge as a reliable aging biomarker, outperforming first-generation clocks.
Novartis scores sixth Cosentyx approval from FDA, this time to treat hidradenitis suppurativa
Novartis on Tuesday nabbed another indication for its biologic Cosentyx (secukinumab), this time in the growing field of treatments targeting the skin condition hidradenitis suppurativa
November 2, 2023